Skip to content

Biomark Diagnostics

2 viewers · 30d

Total raised

$2.5M

1 filing since 2025 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $2.5M
ROUNDS
1
INVESTORS
10
FOUNDED
N/A
HQ
N/A
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
2

AI overview

Updated

BioMark Diagnostics Inc. is dedicated to tackling the critical global issue of early cancer detection, particularly focusing on cancers that are notoriously difficult to diagnose, such as lung, breast, and pancreatic cancers. Their diagnostic solutions aim to significantly improve patient outcomes through earlier and more accurate detection, which is essential for effective treatment and increased survival rates.

What sets it apart

Non-invasive liquid biopsy approach

Funding history

1 round
Equity+2Mar 26, 2025
Form D
+$2.5M$2.5M total

Latest SEC filings

via EDGAR · CIK 0002064257
Form D · Mar 26, 2025View on EDGAR

Products

1 tracked

Liquid Biopsy Diagnostic Technologies

In-vitro diagnostics

BioMark specializes in cutting-edge liquid biopsy diagnostic technologies that harness the power of metabolomics and machine learning to detect cancer-associated biomarkers from simple blood samples. By analyzing these biomarkers, the platform enables early-stage cancer detection, monitors patient responses to treatments, and facilitates routine monitoring for cancer survivors.

  • Early-stage cancer detection
  • Monitoring patient responses to treatments
  • Routine cancer survivor monitoring
  • Non-invasive blood draw

Links

WebsiteSEC EDGAR filings